Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The CEC5 (ALLIANCE A221208) Phase II Study of Corticosteroid + Bevacizumab vs Corticosteroid + Placebo (BeST) for Radionecrosis after Radiosurgery for Brain Metastases trial has permanently closed.
New ways to connect with CCTG have recently launched. CCTG is now on Instagram and Threads. The Threads app is built on the Instagram network and we have begun accounts on both platforms. Instagram and Threads is where we hope everyone in our Cancer research community can come together to discuss our research and support each others work. You can follow and connect directly with our accounts and we will make sure to follow you back.
Please save the date for the 2024 Annual Spring Meeting of Participants which will be held at the Chelsea Hotel from Friday, May 3 to Sunday, May, 5.
The spring meeting is the place for the network members to share ideas, work on trial concepts or ongoing studies, hear about the latest tools and approaches in cancer clinical research, and determine future research directions for the group. More information will be coming soon so stay tuned!
An international study has now opened in Canada that will evaluate if immunotherapy prevents tumour recurrence or spread in early-stage endometrial cancer. The researchers want to compare the effects of a new drug in combination with radiation therapy compared to the current standard treatment of radiation therapy alone for endometrial cancer.
Dr. Joseph Pater has been recognized for a lifetime of work in cancer research with his appointment as an Officer of the Order of Canada. The honor acknowledges the impact of his dedication to clinical research which has improved the lives of Canadians with cancer.
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer
